Related Experiment Video

Updated: Aug 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

[Synergic effect in mechanical and pharmacologic treatments of acute coronary syndromes]

Manuel Gil Moreno1

  • 1Instituto Nacional de Cardiología Ignacio Chávez INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D. F. gil@cardiologia.org.mx

Archivos De Cardiologia De Mexico
|September 12, 2003
PubMed

Insights

Antiplatelet and anticoagulant drugs significantly reduce complications from percutaneous coronary interventions for Acute Coronary Syndromes. These therapies, including aspirin and heparins, are crucial for managing thrombotic responses and improving patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Medicine

Background:

  • Percutaneous coronary intervention (PCI) is the primary treatment for Acute Coronary Syndromes (ACS).
  • Platelets and fibrin formation are key in ACS pathophysiology and PCI-related complications.
  • Controlling thrombotic and clotting responses is vital for managing ACS.

Purpose of the Study:

  • To highlight the importance of antiplatelet and anticoagulant therapies in conjunction with PCI for ACS.
  • To underscore the role of these drugs in mitigating procedural complications and improving clinical outcomes.

Main Methods:

  • Review of the role of platelets and fibrin in ACS and PCI.
  • Analysis of the synergistic effects of pharmacologic agents with PCI.
  • Evaluation of the impact of antiplatelet and anticoagulant drugs on patient outcomes.

Main Results:

  • Pharmacologic agents targeting thrombotic pathways significantly reduce recurrent myocardial infarction, mortality, and re-intervention rates.
  • Combination therapy with PCI and drugs like aspirin, clopidogrel, heparins, and IIb/IIIa blockers is highly effective.
  • These therapies are integral to managing Ischemic Coronary Syndromes.

Conclusions:

  • Antiplatelet and anticoagulant therapies are essential adjuncts to PCI in managing ACS.
  • These pharmacologic interventions substantially improve outcomes by reducing thrombotic complications.
  • Therapeutic strategies for Ischemic Coronary Syndromes must incorporate these agents for optimal patient care.

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...